Angelini Ventures
VC Fund
Rome, Italy
Angelini Ventures is an investment firm.
- Total investments:
- 35
- Last investment:
- Lead investor:
- 37%
Last updated:
For AI agents: llms.txt
Industries Angelini Ventures invests in
Stages Angelini Ventures invests in
Countries Angelini Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $3.3M–$45M
- Series A
- $11M–$105M
- Series B
- $19M–$132M
Investment Focus
Industry
- Health Care 16 (46%)
- Biotechnology 10 (29%)
- Medical 9 (26%)
- Therapeutics 7 (20%)
- Medical Device 5 (14%)
Stage
- Series A 11 (31%)
- Seed 6 (17%)
- Series B 6 (17%)
- Series C 4 (11%)
- Venture - Series Unknown 2 (6%)
Country
- United States 10 (29%)
- Italy 5 (14%)
- France 2 (6%)
- Switzerland 2 (6%)
- United Kingdom 2 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Nils Bottler
Principal
|
Principal | Total investments: 1 | Find email | |
Paolo Di Giorgio
Chief Executive Officer & Managing Director
|
Chief Executive Officer & Managing Director | Total investments: 4 | Find email | |
Regina Hodits
Managing Director
|
Managing Director | Total investments: 15 | Find email | |
Sarah Fox
Investor
|
Investor | Total investments: 1 | Find email | |
Sergio Di Condojanni
Chief Executive Officer
|
Chief Executive Officer | Total investments: 3 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Aptadir Therapeutics is developing RNA inhibitor-based therapeutics for treating intractable cancers and genetic conditions. | $45.5M / Seed / Sep 29, 2026 | ||
| We believe that all patients deserve the most innovative, open surgical treatment options so they can live their fullest lives. We’re on a mission to advance robotic technology that pushes the limits of soft tissue open surgery and opens new opportunities for surgeons to restore quality of life for more patients with complex conditions. TheSymani® Surgical System is a first-of-its kind robotic technology that uniquely addresses the scale and complexities of microsurgery and supermicrosurgery to restore quality of life for more patients. | $19.6M / Venture - Series Unknown / Sep 16, 2026 | ||
| The Gene Expression Modulation System (GEMS) technology from Epic-Bio combines a DNA-binding protein, a tailored guide RNA, and any of a wide range of modulator proteins to generate a powerful new type of genetic medicine. GEMS medicines have the ability to precisely modify gene expression both in and out of the body. They are mutation-independent,which means that a single GEMS design can address the majority or all genetic subtypes of a disease. | $90M / Series C / Aug 11, 2026 | ||
| Handspring is redesigning the family mental healthcare experience from the ground up. Our omnichannel care delivery model tightly integrates different modalities of care, including in-person, digital and devices. Through the use of technology, health plan partnerships, and highly trained clinicians. Handspring Health aims to make quality mentalhealthcare more accessible to all families. | $19M / Series B / Jul 07, 2026 | ||
| Cour Pharmaceuticals Development Co Inc operates in the pharmaceutical sector. Cour Pharmaceuticals Development Co Inc was founded in 2012 and is based in Elmhurst, Illinois. | $50M / Series B / Jun 18, 2026 | ||
| Rosso is a startup dedicated to eliminating the blood shortage crisis in Italy by serving as a connective tissue in the blood supply chain, collaborating with schools, universities, donor associations, and hospitals. Our primary goal is to reduce patient wait times by increasing the number of donors, particularly young donors.Currently,Generation Z is not donating blood significantly; the average donor age is 45, while donation is allowed from 18 to 65 years old. Through innovative social media campaigns and a booking platform, we raise awareness among young people, encouraging them to book donations at nearby centers and providing instant chat access with hematologists to address their concerns.For companies, we offer a welfare service and sustainability membership that engages employees in health prevention and blood donation. We organize awareness webinars, donation days, and monitor employee health, providing impact reports. These activities are included in the company's sustainability report and contribute to B-Corp certification.Our third pillar involves management software for hospitals. We offer a plugin that optimizes blood stock management in hospitals by managing donor portfolios and the relationships between donors, associations, and hospitals. By knowing the blood stock levels, we can send automatic recalls or alerts when blood is needed and there are donors nearby ready to donate. With the help of AI, we can predict future blood stock needs, required blood types, and the timing of potential shortages. | $3.5M / Seed / Jun 10, 2026 | ||
| NUCLIDIUM is a clinical-stage radiopharmaceutical company that develops novel radionuclide PET tracers for precision diagnostics. Using copper isotopes, Copper-61 for diagnostics and Copper-67 for therapeutics, the company is creating a differentiated platform with the potential to overcome existing limitations in radiotheranostics. | $33.6M / Series B / May 28, 2026 | ||
| Making surgeries more precise, safer and faster. Guiding the future of surgery using AI-powered hyperspectral imaging. | $23M / Series A / Apr 29, 2026 | ||
| Laigo Bio uses E3 ligase internalization to precisely degrade membrane proteins linked to autoimmune and inflammatory disorders. | $6.4M / Seed / Mar 23, 2026 | ||
| Laigo Bio uses E3 ligase internalization to precisely degrade membrane proteins linked to autoimmune and inflammatory disorders. | $13.4M / Seed / Dec 03, 2025 | ||
| See all 35 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Angelini Ventures invest in?
Angelini Ventures invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Seed stage. Most of the 35 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Angelini Ventures's check size?
Angelini Ventures typically joins rounds of $3.3M–$45M at Seed, $11M–$105M at Series A and $19M–$132M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Angelini Ventures participates in.
How do I contact Angelini Ventures?
Public channels for Angelini Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Angelini Ventures?
The team at Angelini Ventures includes Nils Bottler (Principal), Paolo Di Giorgio (Chief Executive Officer & Managing Director) and Regina Hodits (Managing Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
